Effects of Ultrasound-Guided Paravertebral Block on MMP-9 and Postoperative Pain in Patients Undergoing VATS Lobectomy: A Randomized, Controlled Clinical Trial

CURRENT STATUS: UNDER REVIEW

BMC Anesthesiology  △ BMC Series

Haichen Chu  
The Affiliated Hospital of Qingdao University

He Dong  
The Affiliated Hospital of Qingdao University

Yongjie Wang  
The Affiliated Hospital of Qingdao University

Zejun Niu  
nzj16niu@sina.com  
The Affiliated Hospital of Qingdao University  
Corresponding Author  
ORCID: 0000-0003-1717-2442

DOI: 10.21203/rs.2.18752/v1

SUBJECT AREAS  
Anesthesiology & Pain Medicine

KEYWORDS  
video-assisted thoracoscopic lobectomy, paravertebral anesthesia, matrix metalloproteinase-9, pain, operative
Abstract

**Background:** Local anesthesia can reduce the response to surgical stress and decrease the consumption of opioids, which may reduce immunosuppression and potentially delay postoperative tumor recurrence. We compared paravertebral block (PVB) combined with general anesthesia (GA) and general anesthesia regarding their effects on matrix metalloproteinase-9 (MMP-9) and postoperative pain after video-assisted thoracoscopic surgery (VATS) lobectomy.

**Methods:** 54 patients undergoing elective VATS lobectomy at a single tertiary care, teaching hospital located in Qingdao between May 2, 2018, and Sep 28, 2018, were randomised by computer to either paravertebral block combined with general anesthesia or general anesthesia. The primary outcome was pain scores during postoperative 48h. The secondary outcome were plasma concentrations of MMP-9, complications, and duration of postoperative hospital stay.

**Results:** 75 were enrolled to the study, of whom 21 were excluded before surgery. We analyzed lobectomy patients undergoing paravertebral block combined with general anesthesia (n=25) or general anesthesia (n=24). Both groups were similar regarding baseline characteristics. Pain scores were lower at 4h and 24h in PVB/GA group, compared with GA group (2.53±0.83 vs 3.4±0.91; 2.2±0.94 vs 3.0±0.93, respectively, *P*<0.05). There were no difference at 1h and 48h between groups. Patients in the PVB/GA group showed a greater decrease in plasma MMP-9 level at T1 and T2 after VATS lobectomy (*P*<0.05). Postoperative complications and length of stay did not differ by anesthetic technique.

**Conclusions:** The paravertebral block/general anesthesia can provide statistically better pain relief and attenuate MMP-9 response to surgery and after VATS.
lobectomy. This technique may be beneficial for patients to recover rapidly after lung surgery and reduce postoperative tumor recurrence.

Background

Lung cancer is the leading cause of death from cancer worldwide, and non-small cell lung cancer (NSCLC) is the most common type (1). Surgery is still the effective treatment for lung cancer. Even if the tumors are complete resected including systemic lymph node dissection, there is still a high rate of tumor recurrence due to undetected micro-metastasis(2–4). Although general anesthesia is the most commonly used anesthesia method in patients undergoing lung resection, general anesthesia is associated with higher levels of inflammation and has stronger immunosuppression in comparison with regional anesthesia(5). The use of a nerve block technique, such as the paravertebral block by modulating the inflammatory and immune response associated with the surgical trauma, reducing opioid and general anesthetic consumption, could be associated with improvements in long-term survival after lung cancer surgery (6).

The matrix metalloproteinase (MMP) family plays an important role in tumor recurrence. MMP-9 is the most detected in a variety of malignant tissues and is associated with tumor metastasis and recurrence potential (7).

Immunohistochemical expression and increased plasma levels of MMP-9 have been demonstrated in NSCLC patients(8). However, to the best of our knowledge, a comparision of the effects of ultrasound-guided paravertebral block combined with general anesthesia and general anesthesia on postoperative pain scores and MMP-9 in VATS lobectomy is rare. Therefore, we compared the effect of PVB/general anesthesia and general anesthesia on pain scores, MMP-9, postoperative
complications and length of stay after VATS lobectomy.

Methods

The study was approved by the Medical Ethics Committee of the Affiliated Hospital of Qingdao University and was performed between May 2018 and Sep 2018. Informed written consent was signed by every patient prior to enrollment in this study. Our study was registered with Chinese Clinical Trial Registry (ChiCTR1800016379). All study procedures were completed at the affiliated hospital of Qingdao university, a tertiary care, teaching hospital located in Qingdao, China. The surgical procedures performed included VATS lobectomy and systematic mediastinal lymphadenectomy.

The inclusion criteria included the following: patients with lung tumors who were undergoing VATS lobectomy, aged 18-70 years, of both genders, American Society of Anesthesiologists physiological status I to III. The exclusion criteria were used: body mass index ≥30 kg/m², anatomical abnormalities of the thoracic spine identified by chest computed tomography, spontaneous pneumothorax in the medical history, known allergy or hypersensitivity against amino-amide local anesthetics (LA), use of nonsteroidal anti-inflammatory drugs 2 weeks before surgery, coagulopathies in the medical history. Seventy-five patients scheduled for VATS lobectomy completed. 54 patients undergoing elective VATS lobectomy were randomized by computer to either PVB/GA (n=27) or GA (n=27). Two PVB patients who was with failed PVB and converted to open surgery did not participate in the final analysis. Three GA patients dropped out after randomization. We finally analyzed patients undergoing PVB/GA (n=25) or GA (n=24). Perioperative data were collected by anesthesia personnel (residents, nurse anesthetists and attendings).
Thoracic paravertebral block technique

We performed ultrasound-guided two-shot paravertebral blocks with 20 ml ropivacaine 0.375% at the thoracic interspace T4-5 and T7-8. We used long-axis (transverse approach) in-plane techniques for thoracic paravertebral nerve block. The ultrasound-guided injection of LA inside the thoracic paravertebral space (TPVS) was performed under direct ultrasound guidance using a transportable ultrasound system (SonoSite M-Turbo, SonoSite Inc., Bothell, WA) with a 80-mm 7-15 MHz linear ultrasound transducer in a lateral position with the scheduled blocking area above. At the T4 and T7 levels, the TPVS was visualized and the needle can be inserted in-plane between the superior costotransverse ligament and the pleura. The puncture area and the ultrasound probe were prepared in a sterile manner, and a skin wheal was performed with 2 ml ropivacaine 0.375% (AstraZeneca AB, PS05070, Sweden). Then, the puncture was performed with a 22-G, 80-mm Facette tip needle and an injection line (Stimuplex D Plus, 0.71 x 80 mm, 22G x 3 ⅛,” B.Braun Melsungen AG, Germany) realizing an “in-plane” ultrasound guided technique as described in a recent study(9). The cable of the needle was not used for stimulation purposes. Once the tip of the needle passed through superior costotransverse ligament and was placed inside the TPVS, 20 ml ropivacaine 0.375% (each injection point) was administered after negative aspiration under direct ultrasound imaging.

Intraoperative and postoperative management

On the day of surgery, investigators generated the randomization sequence using a computerized program. The allocation was concealed until shortly before surgery. An anesthesiologist who was not involved in this study placed the assignment numbers in opaque sealed envelopes to conceal the randomization sequence. All cases were allocated at random to one of two group: a control group (group GA),
receiving general anesthesia and postoperative patient-controlled intravenous analgesia (PCIA), and a treatment group (group PVB), receiving light general anesthesia and intraoperative paravertebral anesthesia and postoperative PCIA. Medical Ethics Committee approval and written informed consent were obtained. All patients were conducted by same anesthesiologist who had considerable prior experience with use of PVB.

In both groups, induction of anesthesia was performed with propofol (1-2 mg/kg), sufentanil (0.4-0.5μg/kg), and cisatracurium (0.15-0.2 mg/kg) for muscle paralysis. After tracheal intubation, maintenance of anesthesia was performed with sevoflurane (1%) in a mixed oxygen/air fresh gas, and cisatracurium as needed in both groups. Analgesia was assured by the ropivacaine solution (0.375%) in the PVB group and by sufentanil as needed in the GA group.

Each patient was intravenous injection of flurbiprofen 50 mg at 30 minutes before the end of surgery. When the surgery is finished, all patients were transferred to the postanesthesia care unit (PACU). All patients who were awake were connected with the PCIA pump with sufentanil and ondansetron. Sufentanil was inserted with 1-2μg/h. A bolus of 2 mL was allowed at every 15 minutes up to a maximal dose of 10μg/h.

All patients were treated with IV flurbiprofen in 50-100 mg increments for a Visual Analog Scale (VAS) score of 4/10 or greater or patient request for analgesia.

Patients were monitored in the PACU until they met discharge criteria.

**Outcomes**

Our primary end point was pain scores at rest. A VAS was used to assess pain intensity at 1, 4, 24 and 48 h after completion of surgery. and The secondary outcomes were plasma concentrations of MMP-9. Postoperative complications
including pneumonia, atelectasis, air leak, atrial fibrillation, hypotension and postoperative nausea and vomiting (PONV) and postoperative hospital stay were recorded.

Blood samples were obtained 10 min before anesthesia (T0), at the end of surgery (T1), and at 12 h after operation (T2). Blood was collected into EDTA tubes and centrifuged at 4000 g for 15 min at 4°C immediately after sampling. Thereafter, plasma was stored at -70°C until all the samples were collected. Plasma concentrations of MMP-9 were measured with commercially quantitative sandwich ELISA kits (Wuhan USCN Business Co., Ltd, Wuhan, China). Standards were prepared, and the appropriate volume of sample or standard was added to a 96-well polystyrene microtitre plate, and incubated for 1 hr at 37°C. Unbound material was removed. Detection Reagent A (biotin-conjugated antibody specific to target protein) was added to each well, and the incubation was continued for 37°C. After washing with wash buffer 3 times, Detection Reagent B (avidin conjugated HRP) was added to each well, and the incubation was continued for 0.5 hr at 37°C. After washing with wash buffer 5 times, TMB substrate was added to each well, and the incubation was continued for 10-20 mins at 37°C. Once 50μl stop solution was added to each well, and the absorbance at 450 nm was measured.

Seven known concentrations, ranging from 0.156 to 10 ng/ml was measured for MMP-9. Samples values was used for further statistical analysis. The concentration of target protein in the samples is then determined by comparing the O.D. of the sample to the standard curve.

Demographic information (age, sex, body mass index, and the American Society of Anesthesiologists grade) and pertinent surgical information (operation time, estimated blood loss) were recorded.
Prospectively collected data included pain scores at 1, 4, 24 and 48 h after completion of surgery, complications (pneumonia, atelectasis, air leak, atrial fibrillation, hypotension, PONV), and length of stay. Both groups received PCA using a mixture of 1μg/mL sufentanil and 0.08mg/mL ondansetron with the pump set to deliver doses of 1-2μg/h intravenous sufentanil with a 15-min lockout time. Nausea and vomiting were treated with intravenous 8 mg ondansetron. Oral liquid on the first day after surgery, and a semi-liquid diet after venting Oral fluids were started at postoperative day 1. The early postoperative diet was initiated at postoperative passage of flatus. All patients were subjected to enforced early mobilization.

Perioperative management was similar in both groups.

**Statistical analysis**

The sample size calculation was based on mean VAS scores (2.53±0.83) from our hospital in the pilot study. To have a greater than 90% power with an overall 2-sided type I error rate of 5%, and consider withdrawal and loss of follow-up (cases of 10%), at least 22 patients were required in each group.

Continuous variables were expressed as the mean (± 1 standard deviation) or median (95% confidence interval (CI)) when data were not normally distributed and were compared between the two groups using the Mann-Whitney U test. \( P < 0.05 \) was considered significant for all data. Data were analyzed by use of the statistical package for the social sciences (SPSS 23.0).

**Results**

Between May 2, 2018 and September 28, 2018, 75 consecutive patients were assessed for eligibility. Twenty-one patients did not meet the inclusion criteria or refused to participate. The remaining 54 patients provided written consent to
participate and were randomized to either group PVB (n=27) or group GA (n=27). Two PVB patients who was with failed PVB and converted to open surgery did not participate in the final analysis. Three GA patients dropped out after randomization. Final analysis compared therefore 25 PVB patients with 24 GA patients (Fig. 1). All subjects were included in the primary outcome analysis. There were no clinically significant differences in demographic data between groups, except for the intraoperative consumption of sufentanil (Table 1).

**Pain Scores**

Visual analogue scale pain scores (at rest) after VATS lobectomy are shown in Figure 2. Compared with the GA group, postoperative VAS pain scores at 4h [2.53±0.83 (95%CI: 2.20 to 2.86) vs 3.4±0.91 (3.04 to 3.76) respectively, \( P =0.011 \)] and 24h [2.2±0.94 (1.83 to 2.57) vs 3.0±0.93 (2.63 to 3.37), \( P =0.026 \)] were lower in the PVB group. VAS scores at 1h and 48h were 2.0 1.0 (95%: 1.60 to 2.40) vs 2.3 0.9 (1.97 to 2.69) and 2.6 1.0 (2.22 to 2.98) vs 2.3 1.0 (1.91 to 2.69) respectively. There was no statistically significant difference in pain scores between the two groups at 1h and 48h after surgery.

**Plasma concentrations of MMP-9**

Mean plasma MMP-9 concentrations at three different time points are shown in Figure 3. Preoperative MMP-9 did not differ between the PVB group and the GA group [94±24 (95%: 85 to103) vs 99±13 (94 to 104) respectively, \( P=0.743 \)]. Plasma MMP-9 concentrations increased significantly after surgery compared to preoperative values. Plasma MMP-9 concentrations at T1 and T2 in the PVB group were significantly lower after surgery than in the GA group [142±53 ng/mL(95%CI: 140 to 144) vs 236±69 ng/mL(208 to 264) at T1 respectively, \( P=0.019 \); 238±53ng/mL(95%CI: 217 to 259) vs 307±16 ng/mL(301 to 313) at T2 respectively,
Complications and length of stay

Postoperative complications are shown in Table 2. Composite complications were uncommon (0-12.5% frequency) and didn’t differ between groups. Although GA group has an increasing trend in postoperative nausea and vomiting (PONV), there was no difference between groups. Mean postoperative hospital stay was not statistically different between the groups (5.3±1.3 days in the PVB group vs. 5.1±1.6 days in the GA group; \( P=0.647 \)).

Discussion

Our results showed that VAS pain scores at postoperative 4 h and 24 h were lower in the PVB/GA group. At the same time, plasma MMP-9 levels at the end of surgery and at postoperative 12 h were also significantly decreased in the PVB/GA group after VATS lobectomy. There was no difference in VAS between the groups at postoperative 1 h and 48 h. Postoperative complications and the length of hospital stay were not different between the two groups. Although there was an increasing trend in PONV in GA group, there’s no statistics difference in PVB group and GA group.

Surgery is the most effective treatment for lung cancer. However, effective analgesia allows patients to recover quickly. Paravertebral nerve block combined with general anesthesia reduces patients' immunosuppression and the consumption of sufentanil. Ropivacaine is a long-acting local anesthetic, and its action time can reach 12-24 hours. This study showed that patients at the end of surgery had similar VAS scores between groups and that the analgesia effect of paravertebral block was similar to that of sufentanil. But PVB has no immunosuppressive effect.
The analgesia scores at 4 and 12 hours after surgery were lower in the PVB group, which was related to the longer duration of ropivacaine action. Although the tumor is surgically removed, micro-metastasis is inevitable, especially when the patient's immune function is suppressed. Retrospective studies suggest regional anesthesia including nerve block reduces tumor metastasis and recurrence in various cancers(10–12). Paravertebral block and postoperative analgesia can reduce the risk of recurrence and metastasis in breast cancer patients during the initial years of follow-up after mammectomy(10). Our study showed that the PVB group had significantly lower VAS scores than the GA group at postoperative 4 h and 24 h during thoracoscopic lobectomy. The low operative VAS score at 4 h and 24 h may be attributed to the effect of ropivacaine on the paravertebral space for up to 24 hours. Similar pain scores at 1 h were associated with intravenous injection of flurbiprofen at 30 min before the end of surgery. Better analgesia (for example combined PVB) reduces intraoperative consumption of sufentanil. It is well known that opioids can suppress immune function, which may affect tumor metastasis and recurrence. The reasons that opioids promote tumor growth and metastasis are based on the modulation of cellular and humoral responses leading to immunosuppression(13) and the direct action on tumor cells and immune or endothelial cells(14). The immunosuppressive effect of opioids is independent of their antinociceptive effect. Therefore, it is essential to individually evaluate the effect of opioids on the immune system. During thoracoscopic lobectomy we chose paravertebral nerve block combined GA so that we can decrease the dose of sufentanil and potentially reduced the inhibition of immune function. If we choose postoperative PVB analgesia, patients in PVB group will have a better recovery. MMP-9 is a member of the MMP superfamily and plays an important role in many
pathophysiological processes, such as bone development, wound healing, cell migration, cancer invasion and metastasis (15). The surgery trauma resulted in increased plasma MMP-9. Our results supported the notion that plasma MMP-9 level increased after VATS lobectomy. PVB inhibited surgical stress and decreased postoperative MMP-9 level. There may be several reasons that PVB decreased plasma MMP-9 level at T1 and T2. First of all, vitro experiments showed local anesthetics have antiproliferative and cytotoxic effects on cancer cells (16–18). Second, paravertebral nerve block and analgesia reduced the risk of breast cancer recurrence or metastasis 4-fold during a four-year follow-up (10). Moreover, our observations that reductions in MMP-9 at T1 and T2 were greater when patients received combined paravertebral anesthesia with general anesthesia seem consistent with the hypothesis that PVB has little effect on immune function, thus strengthens immune defenses against tumor progression. Thereby, MMP-9 level in the PVB/GA group was lower during VATS lobectomy. Another possible mechanism by which PVB may decrease MMP-9 is that thoracic paravertebral block reduced the level of inflammatory factors and the surgical stress response. Therefore, general anesthesia combined with PVB methods undergoing VATS lobectomy can reduce MMP-9 levels, provide better postoperative analgesia, and should be recommended. Although GA group had a high consumption of sufentanil during lobectomy, postoperative complications such as nausea, vomiting, and respiratory depression were not different between the two groups. Previous studies (19, 20) demonstrated the PVB group had a significant reduction in the use of opioids and nerve block can reduce postoperative complications caused by opioids. There could be several reasons for the difference. First, because we did not use PVB as a postoperative analgesia method, the benefits of PVB were not fully shown, such as less pulmonary
complications, hypotension, nausea and vomiting, and urinary retention etc (21). Second, enhanced recovery after VATS lobectomy protocols we used can prevent factors that delay postoperative recovery and issues that cause complications. Similar results from other studies (22). Although previous investigations (23) have demonstrated that PVB is associated with shorter hospitalizations, the length of stay was similar in both groups in our study. Hospital stay is affected by various factors, and different postoperative analgesia methods may also affect the length of hospital stay (23).

Our study has several limitations. First, the surgical procedures carried out were not homogeneous. Although the lobectomy is performed by the same group of surgeons, the individual differences and anatomical abnormalities of the surgical patients will cause slight different degrees of surgical injuries. Secondly, postoperative paravertebral analgesia should be adopted in the PVB group, which can better show the difference between the two groups.

Conclusions

In conclusion, in this prospective randomized clinical trial, PVB combined general anesthesia is accompanied with an attenuation of MMP-9 response to surgery and provided statistically better pain relief after VATS lobectomy. This technique may be beneficial for patients to recover rapidly after lung surgery and reduce tumor recurrence. Further studies are required to investigate this effect could be extended beyond immediate postoperative period by utilizing a continue paravertebral analgesia technique.

Declarations
**Ethics approval and consent to participate:** This study was approved by the Medical Ethics Committee of the Affiliated Hospital of Qingdao University and registered with Chinese Clinical Trial Registry (ChiCTR1800016379). Written informed consent was obtained from all participants prior to inclusion in the study.

**Consent for publication:** Not applicable.

**Availability of data and materials:** The data and materials are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** This work was supported by the Young Science Foundation of the Affiliated Hospital of Qingdao University. The fund provided support in experimental design, implementation, data analysis, and interpretation of data and in writing the manuscript.

**Authors’ contributions:** HC contributed to study design, interpretation of data, and drafted the manuscript, and approved the final version. HD contributed to study design, acquisition of data, and approved the final version. HD and YW were primarily responsible for the processing and analysis of blood samples. YW contributed to study design, critically revised the manuscript, and approved the final version. ZN was responsible for the majority of ELISA experiments, contributed to study design, analysis, and interpretation of the data, revised the manuscript, and approved the final version.

**Acknowledgements:** The authors would like to thank Dr. Xianfei Yan and Guishen Miao for data collection.

**Abbreviations**

PVB: paravertebral block, GA: general anesthesia, MMP-9: matrix metalloproteinase-
9, VATS: video-assisted thoracoscopic surgery, NSCLC: non-small cell lung cancer, TPVS: thoracic paravertebral space, PCIA: patient-controlled intravenous analgesia, PACU: postanesthesia care unit, VAS: visual analog scale, PONV: postoperative nausea and vomiting.

References

1. Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY, Chen LA, et al. Prevention and management of lung cancer in China. Cancer. 2015;121 Suppl 17:3080-8.

2. Kim AW. Lymph node drainage patterns and micrometastasis in lung cancer. Semin Thorac Cardiovasc Surg. 2009;21(4):298-308.

3. Koulaxouzidis G, Karagkiouzis G, Konstantinou M, Gkiozos I, Syrigos K. Sampling versus systematic full lymphatic dissection in surgical treatment of non-small cell lung cancer. Oncol Rev. 2013;7(1):e2.

4. Merchant NN, McKenna R Jr, Onugha O. Is there a role for VATS sleeve lobectomy in lung cancer? Surg Technol Int. 2018;32:225-9.

5. Perez-Gonzalez O, Cuellar-Guzman LF, Soliz J, Cata JP. Impact of Regional Anesthesia on Recurrence, Metastasis, and Immune Response in Breast Cancer Surgery: A Systematic Review of the Literature. Reg Anesth Pain Med. 2017;42(6):751-6.

6. Lee EK, Ahn HJ, Zo JI, Kim K, Jung DM, Park JH. Paravertebral Block Does Not Reduce Cancer Recurrence, but Is Related to Higher Overall Survival in Lung Cancer Surgery: A Retrospective Cohort Study. Anesth Analg. 2017;125(4):1322-8.

7. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression
in non-small-cell lung cancer. Br J Cancer. 2001;85(11):1706-12.

8. Ding G, Liu Y, Liang C. Efficacy of radiotherapy on intermediate and advanced lung cancer and its effect on dynamic changes of serum vascular endothelial growth factor and matrix metalloproteinase-9. Oncol Lett. 2018;16(1):219-24.

9. Marhofer D, Marhofer P, Kettner SC, Fleischmann E, Prayer D, Schernthaner M, et al. Magnetic resonance imaging analysis of the spread of local anesthetic solution after ultrasound-guided lateral thoracic paravertebral blockade: a volunteer study. Anesthesiology. 2013;118(5):1106-12.

10. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660-4.

11. Mao L, Lin S, Lin J. The effects of anesthetics on tumor progression. Int J Physiol Pathophysiol Pharmacol. 2013;5(1):1-10.

12. Sekandarzad MW, van Zundert AAJ, Lirk PB, Doornebal CW, Hollmann MW. Perioperative Anesthesia Care and Tumor Progression. Anesth Analg. 2017;124(5):1697-708.

13. Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids--clinical relevance. J Neuroimmune Pharmacol. 2011;6(4):490-502.

14. Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat MO. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172(2):251-9.

15. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol. 2008;6(3):158-72.

16. Bundscherer A, Malsy M, Gebhardt K, Metterlein T, Plank C, Wiese CH, et al. Effects of ropivacaine, bupivacaine and sufentanil in colon and pancreatic
cancer cells in vitro. Pharmacol Res. 2015;95-96:126-31.

17. Jose C, Bellance N, Chatelain EH, Benard G, Nouette-Gaulain K, Rossignol R. Antiproliferative activity of levobupivacaine and aminoimidazole carboxamide ribonucleotide on human cancer cells of variable bioenergetic profile. Mitochondrion. 2012;12(1):100-9.

18. Jurj A, Tomuleasa C, Tat TT, Berindan-Neagoe I, Vesa SV, Ionescu DC. Antiproliferative and apoptotic effects of lidocaine on human hepatocarcinoma cells. A preliminary study. J Gastrointestin Liver Dis. 2017;26(1):45-50.

19. Clendenen SR, Wehle MJ, Rodriguez GA, Greengrass RA. Paravertebral block provides significant opioid sparing after hand-assisted laparoscopic nephrectomy: an expanded case report of 30 patients. J Endourol. 2009;23(12):1979-83.

20. Fortier S, Hanna HA, Bernard A, Girard C. Comparison between systemic analgesia, continuous wound catheter analgesia and continuous thoracic paravertebral block: a randomised, controlled trial of postthoracotomy pain management. Eur J Anaesthesiol. 2012;29(11):524-30.

21. Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy--a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2006;96(4):418-26.

22. Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017;152(3):292-8.

23. Parikh RP, Sharma K, Guffey R, Myckatyn TM. Preoperative Paravertebral Block Improves Postoperative Pain Control and Reduces Hospital Length of Stay in Patients Undergoing Autologous Breast Reconstruction after Mastectomy for
Tables

Table 1 Demographic Data

| Characteristics            | Group PVB (n=25) | Group GA (n=24) | P Value |
|----------------------------|-----------------|-----------------|---------|
| Age (yr)                   | 58±11           | 59±9            | 0.767   |
| Male, n (%)                | 20 (54)         | 16 (42)         | 0.329   |
| BMI                        | 24±3.6          | 25±3.2          | 0.126   |
| ASA I/II/III               | 5/30/2          | 8/27/3          | 0.595   |
| Operation time (min)       | 138±57          | 129±60          | 0.571   |
| Estimated blood loss (mL)  | 33±12           | 36±13           | 0.558   |
| Sufentanil dosage (μg)     | 37±16           | 68±19           | <0.00   |

Values are shown as mean ± standard deviation or number (n) and %. BMI indicates body mass index; ASA, American Society of Anesthesiologists.

Table 2 Postoperative complications

| Parameter                  | Group PVB n (%) | Group GA n (%) | P-value |
|----------------------------|-----------------|----------------|---------|
| Pneumonia                  | 0               | 1 (4.2)        | 0.490   |
| Atelectasis                | 1 (4.0)         | 2 (8.3)        | 0.527   |
| Air leak                   | 0               | 0              |         |
| AF                         | 2 (8.0)         | 1 (4.2)        | 0.576   |
| Hypotension                | 3 (12.0)        | 2 (8.3)        | 0.672   |
| PONV                       | 1 (4.0)         | 3 (12.5)       | 0.277   |

AF: atrial fibrillation. PONV: postoperative nausea and vomiting.

Figures

Figure 1

Protocol for patient enrolment in the study groups. Randomized controlled trial c

Figure 2

Postoperative pain scores. Pain was assessed by the use of a VAS ranging from 0

Figure 3

Plasma concentration of measured MMP-9 in lung cancer patients receiving PVB c
Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

CONSORT 2010 Checklist.doc